用最佳-最差标度法确定慢性皮肤病核心结局域
该横断面研究通过互联网调查美国成人慢性皮肤病患者,采用最佳-最差标度法对PROMIS域进行偏好评分,共939人参与。结果显示身体意象、外观、生活满意度、瘙痒、疼痛、焦虑和抑郁在各病种中评分较高,有助于构建高效捕捉慢性皮肤病体验的PROMIS简表。
要点
- 身体意象、外观、生活满意度、瘙痒和疼痛是慢性皮肤病患者最重视的PROMIS域。
- 痤疮患者最重视身体意象(15.66)和外观(14.96),银屑病患者最重视生活满意度(11.31)。
- 特应性皮炎患者最重视瘙痒(12.60),其次为生活满意度(11.65)和外观(11.40)。
核心结论
- 身体意象、外观、生活满意度、瘙痒、疼痛、焦虑和抑郁是慢性皮肤病患者高度评价的PROMIS域。
- 识别这些域可帮助临床医生选择最相关的患者报告结局测量,并指导构建有效捕捉疾病体验的PROMIS简表。
研究设计与样本
- 横断面研究,基于互联网调查美国成人慢性皮肤病患者。
- 通过文献回顾制定与慢性皮肤病相关的PROMIS域列表,并纳入最佳-最差标度练习。
- 共939名参与者完成调查,调查时间为2022年12月至2023年6月,数据分析于2023年6月进行。
主要发现
- 痤疮患者评分最高的域为身体意象(15.66)、外观(14.96)、生活满意度(11.29)、抑郁(9.25)和焦虑(9.18)。
- 银屑病患者评分最高的域为生活满意度(11.31)、外观(11.05)、瘙痒(10.98)、疼痛(9.97)和身体意象(8.75)。
- 特应性皮炎患者评分最高的域为瘙痒(12.60)、生活满意度(11.65)、外观(11.40)、身体意象(11.25)和疼痛(10.03)。
关键数值与推荐
- 使用最佳-最差标度法对12组每组4个域进行选择,计算每个域的比率标度偏好评分。
临床怎么用
- 临床医生可根据患者所患疾病选择最相关的PROMIS域进行患者报告结局测量。
- 研究结果可指导构建有效捕捉慢性皮肤病体验的PROMIS简表,作为疾病严重度和治疗效果的的患者报告测量工具。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The use of patient-reported outcome measures (PROMs) potentially holds promise as an opportunity to improve outcomes and quality of care for patients with skin disease, but the routine use of PROMs remains limited. While the Patient-Reported Outcomes Measurement Information System (PROMIS) has several strengths and domains relevant to those with chronic skin disease, it is not clear which are most useful. OBJECTIVE: To determine which PROMIS domains are most meaningful to those with chronic skin disease to develop a PROMIS profile that effectively captures the experience of living with these skin diseases. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study was based on data gathered from an internet survey that was administered to a sample of adult respondents in the US on the Prolific Platform and ResearchMatch and through the National Psoriasis Foundation. A list of PROMIS domains relevant to chronic skin disease was developed through literature review. These domains were included in a best-worst scaling exercise, in which participants were shown 12 sets of 4 domains and asked to choose which domain in each set was the most important and least important to their experience. Participants completed the survey between December 2022 and June 2023. Data were analyzed in June 2023. MAIN OUTCOMES AND MEASURES: Ratio-scaled preference score for each of the domains. RESULTS: Of 939 total participants, 559 (59.5%) were female, 20 (2.1%) gender nonconforming, 7 (0.7%) transgender men, and 1 (0.1%) transgender women; there were 4 American Indian/Alaska Native (0.4%), 50 Asian (5.3%), 63 Black (6.7%), 66 Hispanic or Latino/a/x (7.0%), 2 Native Hawaiian/Pacific Islander (0.2%), 749 White (79.8%), and 42 multiracial individuals (4.5%). The survey was completed by 200 participants with acne, 316 with psoriasis, 199 with atopic dermatitis, and 224 with various chronic skin diseases. For those with acne, the highest-scored domains were body image (15.66), appearance (14.96), life satisfaction (11.29), depression (9.25), and anxiety (9.18). For those with psoriasis, the highest-scored domains were life satisfaction (11.31), appearance (11.05), itch (10.98), pain (9.97), and body image (8.75). For those with atopic dermatitis, the highest-scored domains were itch (12.60), life satisfaction (11.65), appearance (11.40), body image (11.25), and pain (10.03). CONCLUSION AND RELEVANCE: The results of this study suggest that body image, appearance, life satisfaction, itch, pain, anxiety, and depression were highly rated across the surveys. By identifying the PROMIS domains most important to individuals with chronic skin disease, clinicians can choose the domains that are most relevant to patients. In addition, this may guide the construction of a PROMIS profile that effectively captures the experience of living with these skin diseases and can serve as a patient-reported measure of disease severity and treatment effectiveness.
引用
- Shields A, Barg FK, Begolka WS, et al. Identifying Core Outcome Domains in Chronic Skin Disease Using the Best-Worst Scaling Method. JAMA Dermatol. 2024. PMID: 38381409. doi:10.1001/jamadermatol.2023.6245
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。